4-{([(4'-isopropylphenyl)amino]carbonyl)amino}benzenesulfonamide | 889244-14-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 4-{([(4'-isopropylphenyl)amino]carbonyl)amino}benzenesulfonamide
• 英文别名: 4-(3-(4-Isopropylphenyl)ureido)benzenesulfonamide；1-(4-propan-2-ylphenyl)-3-(4-sulfamoylphenyl)urea
• CAS: 889244-14-8
• 化学式: C₁₆H₁₉N₃O₃S
• 分子量: 333.411
• InChiKey: LQPSERXJEQNKFO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  23
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.19
• 拓扑面积：
  110
• 氢给体数：
  3
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  4-异丙基苯异氰酸酯 、 磺胺 以 乙腈 为溶剂， 以58.5%的产率得到4-{([(4'-isopropylphenyl)amino]carbonyl)amino}benzenesulfonamide
  参考文献：
  名称：

  脲基取代的苯磺酰胺有效抑制碳酸酐酶IX并在乳腺癌转移模型中显示抗转移活性。

  摘要：

  制备了一系列脲基取代的苯磺酰胺，它们对抑制几种人类碳酸酐酶（hCAs，EC 4.2.1.1）表现出非常有趣的特性，例如hCAs I和II（胞质同工型）以及hCAs IX和XII（跨膜，肿瘤相关酶）。在该系列的各种成员中，根据脲部分的取代方式，已观察到对所有这些同工型的优异抑制作用。已经发现了几种低纳摩尔浓度的CA IX / XII抑制剂，它们相对于胞质同工型对跨膜也显示出良好的选择性。其中一种是4-{[（（3'-硝基苯基）氨基甲酰基]氨基}苯磺酰胺，在药理浓度为45 mg / kg时，可高度抑制高侵袭性4T1乳腺肿瘤细胞转移的形成，

  DOI：

  10.1021/jm101541x

文献信息

• [EN] NOVEL SULFONAMIDE COMPOUNDS FOR INHIBITION OF METASTATIC TUMOR GROWTH<br/>[FR] NOUVEAUX COMPOSÉS DE SULFONAMIDE DESTINÉS À L'INHIBITION DE LA CROISSANCE TUMORALE MÉTASTATIQUE
  申请人：METASIGNAL THERAPEUTICS INC

  公开号：WO2012021963A1

  公开（公告）日：2012-02-23

  Therapeutic sulfonamide compounds with the formula R-Q-Ar-SO2NH2 are disclosed, wherein R is an aryl, hetaryl, alkyl or cycloalkyl group, Q is the group -L(CH2)n-, wherein n = 0,1 or 2 and L is the group - NHCXNH-, -NHC(S)SNH-, -NHCONHCSNH- or -SO2NH-, X is O or S and Ar is a C6-C10 aromatic or a heteroaromatic group that contains at least one heteroatom of oxygen, nitrogen or sulphur, which compounds selectively inhibit CAIX and CAXII, and which are effective in inhibiting hypoxic tumor growth, suppress metastases, and impair and deplete cancer stem cells in mammals.

  揭示了具有R-Q-Ar-SO2NH2分子式的治疗性磺胺化合物，其中R是芳基、杂环基、烷基或环烷基，Q是基团-L(CH2)n-，其中n = 0、1或2，L是基团-NHCXNH-、-NHC(S)SNH-、-NHCONHCSNH-或-SO2NH-，X是O或S，Ar是含有至少一个氧、氮或硫杂原子的C6-C10芳香或杂芳基团，这些化合物选择性抑制CAIX和CAXII，在抑制缺氧肿瘤生长、抑制转移、损害和消耗哺乳动物中的癌干细胞方面具有有效性。
• NOVEL SULFONAMIDE COMPOUNDS FOR INHIBITION OF METASTATIC TUMOR GROWTH
  申请人：METASIGNAL THERAPEUTICS INC.

  公开号：US20130190396A1

  公开（公告）日：2013-07-25

  Therapeutic ureido-sulfonamide compositions having compounds with the formula R-Q-Ar—SO 2 NH 2 are disclosed, which compounds selectively inhibit CAIX and CAXII, and which are effective to inhibit hypoxic tumor growth, suppress metastases, and impair and deplete cancer stem cells in mammals.

  本发明公开了具有以下化学式的化合物的治疗性尿素磺酰胺组合物R-Q-Ar—SO2NH2，这些化合物选择性地抑制CAIX和CAXII，并且有效地抑制哺乳动物中的低氧肿瘤生长，抑制转移并且损害和消耗癌症干细胞。
• Inhibition of β-carbonic anhydrases with ureido-substituted benzenesulfonamides
  作者：Fabio Pacchiano、Fabrizio Carta、Daniela Vullo、Andrea Scozzafava、Claudiu T. Supuran

  DOI：10.1016/j.bmcl.2010.11.064

  日期：2011.1

  A series of sulfonamides was prepared by reaction of sulfanilamide with aryl/alkyl isocyanates. The ureido- substituted benzenesulfonamides showed a very interesting profile for the inhibition of several carbonic anhydrases (CAs, EC 4.2.1.1) such as the human hCA II and three beta-CAs from pathogenic fungal or bacterial species. The Candida albicans enzyme was inhibited with potencies in the range of 3.4-3970 nM, whereas the Mycobacterium tuberculosis enzymes Rv1284 and Rv3273 were inhibited with K(i)s in the range of 4.8-6500 nM and of 6.4-6850 nM, respectively. The structure-activity relationship for this class of inhibitors is rather complex, but the main features associated with effective inhibition of both a-and beta-CAs investigated here have been delineated. The nature of the moiety substituting the second ureido nitrogen is the determining factor in controlling the inhibitory power, probably due to the flexibility of the ureido linker and the possibility of this moiety to orientate in different subpockets of the active site cavities of these enzymes. (C) 2010 Elsevier Ltd. All rights reserved.
• DIANHYDROGALACTITOL TOGETHER WITH RADIATION TO TREAT NON-SMALL-CELL CARCINOMA OF THE LUNG AND GLIOBLASTOMA MULTIFORME
  申请人：Del Mar Pharmaceuticals

  公开号：EP3217970A1

  公开（公告）日：2017-09-20
• USE OF DIANHYDROGALACTITOL AND ANALOGS AND DERIVATIVES THEREOF, TOGETHER WITH RADIATION, TO TREAT NON-SMALL-CELL CARCINOMA OF THE LUNG AND GLIOBLASTOMA MULTIFORME AND SUPPRESS PROLIFERATION OF CANCER STEM CELLS
  申请人：DelMar Pharmaceuticals, Inc.

  公开号：US20190015379A1

  公开（公告）日：2019-01-17

  The use of dianhydrogalactitol provides a novel therapeutic modality for the treatment of non-small-cell lung carcinoma (NSCLC) and for the treatment of glioblastoma multiforme (GBM). Dianhydrogalactitol acts as an alkylating agent on DNA that creates N7 methylation. Dianhydrogalactitol is effective in suppressing the growth of cancer stem cells and is active against tumors that are refractory to temozolomide; the drug acts independently of the MGMT repair mechanism.